Abstract:
PROBLEM TO BE SOLVED: To provide an isolated antibody that binds with greater specificity to an amyloid beta (Aβ) protein globulomer than to an amyloid beta protein monomer.SOLUTION: A monoclonal antibody is produced by a hybridoma having American Type Culture Collection designation number PTA-7238 or PTA-7407, and may be used in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
Abstract:
PROBLEM TO BE SOLVED: To provide a new family of a binding protein, and a human antibody and its fragment, which have a capacity to bind to IL-18, binds with a high affinity, and neutralizes the IL-18 by binding to it.SOLUTION: The present invention includes an IL-18 binding protein, particularly an antibody which binds to a human interleukin-18 (hIL-18). Concretely, the invention relates to an antibody which is an entirely human antibody. The antibody has the high affinity for the hIL-18, and/or neutralizes an hIL-18 activity in vitro and in vivo. The antibody can be of a full-length or an antigen binding portion thereof. The method of making the antibody is also provided. The antibody, or the antibody portion is useful for detecting the hIL-18, and for medically treating a human subject suffering from a disorder in which the hIL-18 is detrimental, based on an hIL-18 activity inhibition.
Abstract:
PROBLEM TO BE SOLVED: To provide a perfect human antibody IL-18 as a preferred IL-18 inhibitor, because parts of a chimera and humanized antibodies still remain as a murine sequence, and therefore, may cause an undesirable immune reaction if they are administered over a long period.SOLUTION: The present invention includes an antigen binding to a human interleukin-18, particularly an antigen binding to an epitope of a human IL-18. The antibody can be, for example, an entirely human antibody, a recombinant antibody, or monoclonal antibody. A preferred antibody has the high affinity for the hIL-18, and/or neutralizes an hIL-18 activity in vitro and in vivo. The antibody can be of a full-length or an antigen binding portion thereof. The methods of making and using the antibody are also provided. The antibody, or the antibody portion is useful for detecting the hIL-18, and also useful, for example, for inhibiting a hIL-18 activity in a human subject suffering from a disorder in which the hIL-18 is detrimental.
Abstract:
PROBLEM TO BE SOLVED: To provide an IL-18 binding protein, especially an antibody binding to human interleukin-18 (hIL-18). SOLUTION: There is provided an antibody which is a perfect human antibody. A preferable antibody has high affinity with hIL-18, or neutralizes the activity of hIL-18 in vitro or in vivo. The antibody may be a total length antibody or an antigen-binding portion thereof. A method for producing the antibody and a method for using the same are also provided. The antibody or antibody portion is useful for detecting hIL-18 and for inhibiting the activity of hIL-18, for example, in a human testee suffering from a disease wherein the activity of the hIL-18 is harmful. COPYRIGHT: (C)2011,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide an antibody which binds to human interleukin-18 (hIL-18), to provide a method for producing the same; and to provide a method for using the same. SOLUTION: There are provided a neutrally binding protein which is an antibody comprising immune globulin heavy chain and light chain having specific amino acid sequences and specifically binding to human IL-18, and has an ability to neutralize IL-18; a method for producing the antibody; and a use for detecting hIL-18 or treating a human testee suffering from a disease wherein the activity of hIL-18 is harmful. COPYRIGHT: (C)2011,JPO&INPIT
Abstract:
The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
Abstract:
Anti-Aß globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-Aß globulomer antibodies having a binding affinity to Aß(20-42) globulomer that is greater than the binding affinity of the antibody to Aß(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
Abstract:
The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.
Abstract:
The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
Abstract:
The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.